
Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars
Alvotech/Teva and Biocon Biologics advanced US biosimilar access with FDA interchangeability for ustekinumab biosimilars, Selarsdi and Yesafili, plus broad 2025 formulary coverage for Biocon’s Yesintek. Alvotech and Teva Secure Interchangeability for …